On its face, the market opportunity for a BPH indication, and its synergies with an ED drug, seemed enormous: both ED and BPH were age-related conditions, and data showed that half of men with ED had BPH symptoms. Moreover, the BPH indication would be taken in the same frequency and dosing as the once-a-day version of Cialis. However, market research had revealed significant challenges in introducing the BPH indication under the Cialis name. For example, although ED and BPH often co-existed, men perceived them quite differently.
- Patients often inquire about differences between Cialis Lilly and other tadalafil brands; efficacy is equivalent.
- Pricing depends on market, insurance, and retailer discounts or promotions.
- Cialis Lilly can be ordered from licensed pharmacies with valid prescription.
- Storage recommendations include protecting from moisture and extreme temperatures.
- Avoid consuming grapefruit products that may interfere with metabolism of tadalafil.
- Cialis Lilly is not intended for recreational use or enhancement without medical diagnosis.
- Alcohol and heavy meals may delay onset of action but do not reduce effectiveness.
- Medical history review is crucial to prevent contraindications.
- Cialis Lilly usage instructions emphasize timing and dose adherence for optimal outcomes.
- Patient feedback and real-world data help improve education and support services.
Some physicians also reacted negatively to the BPH indication. Impending competition from low-price ED generics, given that Viagra would soon be going off patent, underscored the importance of the BPH opportunity. FDA is alerting consumers and health care professionals that counterfeit versions of Cialis 20 mg tablets were found in the mail on its way to a U.S.
- Ongoing research may explore new formulations or delivery methods.
- Studies on its potential effects in other conditions (e.g., Raynaud's) exist.
- Investigation into cardiovascular benefits remains a topic of interest.
- The role of daily tadalafil in early-stage Peyronie's disease is studied.
- Post-generic, Lilly's focus shifted to newer therapeutic areas.
- Real-world data collection continues to inform long-term use patterns.
- Patient adherence and persistence with therapy are research subjects.
- The legacy of Cialis as a blockbuster drug influences pharmaceutical R&D.
consumer.
- Cialis Lilly is indicated for men with erectile dysfunction regardless of age.
- It is also effective in treating lower urinary tract symptoms due to BPH.
- Cialis Lilly improves walking distance in some patients with pulmonary arterial hypertension.
- The medicine should be avoided by patients with severe liver or kidney impairment without consulting a doctor.
- Sexual stimulation is required for Cialis to work effectively.
- Cialis Lilly is distinct from other ED drugs by its dual indication for ED and BPH.
- Some patients experience muscle and back pain which typically resolves within 48 hours.
- Cialis Lilly is contraindicated in men taking nitrates for chest pain.
- The label includes guidance on side effects, contraindications, and precautions.
- Proper diagnosis by a healthcare provider is essential before starting treatment.
While this shipment was stopped, FDA is concerned about other possible mail shipments to consumers.
- Cialis Lilly has been extensively studied, with thousands of patients in clinical trials worldwide.
- Data supports its safety profile when used according to recommendations.
- It has shown positive effects on patient satisfaction and relationship quality.
- Cialis Lilly is compatible with common antihypertensive medications, but care is advised.
- Patients should inform physicians about allergies to tadalafil or other substances.
- Pregnant or breastfeeding women should avoid Cialis Lilly entirely.
- Cialis Lilly should not be shared; it is personalized medication.
- Lifestyle factors such as smoking and obesity influence treatment success.
- Cialis Lilly packaging includes detailed patient leaflets for education.
- It remains a key product in Eli Lilly’s sexual health treatment line.
FDA laboratory analysis showed the counterfeit versions contain multiple active ingredients, which if used could result in adverse effects or harm.
What Are the Key Risks and Uncertainties?
Over the years, Lilly has grown its key ED brand with a great deal of advertising, building an identity around couples in bathtubs in TV ads and elsewhere. But as it nears the end of its patent life, Lilly will likely pull back on advertising. A recent report from Advertising Age said the company and Pfizer are pulling their NFL ad campaigns. How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new indication, benign prostatic hyperplasia (BPH), soon to be carried out, the team had to make a decision soon. Consumers should only buy prescription medicines from state-licensed pharmacies located in the U.S. FDA cannot confirm that the manufacturing, quality, storage, and handling of these products follow U.S. standards because these products are from an unknown source.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Professional | 20mg | 120 + 4 Pills | 291.68€ 277.79€ | |
| Cialis Black | 80mg | 30 + 2 Pills | 89.11€ 84.87€ | |
| Cialis Generic | 20mg | 20 Pills | 54.72€ 52.11€ | |
| Cialis Generic | 20mg | 60 + 6 Pills | 117.76€ 112.15€ | |
| Cialis Original | 20mg | 8 Pills | 61.70€ 58.76€ | |
| Cialis Original | 20mg | 34 + 2 Pills | 183.99€ 175.23€ | |
| Cialis Black | 80mg | 10 Pills | 43.27€ 41.21€ | |
| Cialis Generic | 60mg | 30 + 2 Pills | 85.33€ 81.27€ | |
| Cialis Professional | 20mg | 60 + 2 Pills | 183.83€ 175.08€ | |
| Cialis Professional | 40mg | 90 + 2 Pills | 348.59€ 331.99€ |
Therefore, these products are considered unsafe and should not be used.
| Aspect | Description | Launch Year | Manufacturer | Formulations Available |
|---|---|---|---|---|
| General Information | A popular erectile dysfunction medication | 2003 | Eli Lilly | Tablets, orodispersible |
| Active Ingredient | Tadalafil | N/A | Eli Lilly | Tadalafil |
| Common Uses | Erectile dysfunction, BPH | N/A | Eli Lilly | |
| Market Presence | Widely available globally | N/A | Eli Lilly |
FDA also recommends consumers talk to their health care professional about their condition and options for treatment if they received a counterfeit product. FDA-approved Cialis tablets made by Eli Lilly contain the active ingredient, tadalafil, and are used for the treatment of erectile dysfunction and other approved indications. Currently, Eli Lilly’s authentic product is considered safe and effective for its intended uses.
Tadalafil or Cialis: Are They Basically The Same?
For more information about Menarini Asia-Pacific, please visit: If you'd like to know more about Menarini, feel free to download our PDF files here. Under a new patent settlement with multiple generics makers, Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer. Cialis has generated more than $17 billion in sales during its patent life, which now extends at least through Sept. 27, 2018. Lilly reached the settlement with generic drugmakers over a dispute on a unit dose patent set to expire in 2020.
Pulmonary arterial hypertension
After its initial approval in 2003, Cialis’ exclusivity had been expected to end in November, just a month before Pfizer’s rival med Viagra. With the new agreement, Lilly can work to squeeze more branded sales out of a med that’s been an important contributor over the years. Last year, the drug turned in $1.469 billion in U.S. sales, or 7% of the drugmaker’s global haul. RELATED: Top 10 U.S.
Pricing and Reimbursement
patent losses of 2017 - Cialis In a statement, Lilly’s general counsel Michael Harrington said the “unit dose patent for Cialis is valid and infringed by companies seeking to market a generic version of Cialis.” He added the deal includes a “royalty-bearing license agreement that provides us with more certainty regarding our U.S. exclusivity.” Generics from Aurobindo, Teva Pharmaceutical, Alembic, Watson, Sun Pharma and Synthon are tentatively FDA-approved and ready to roll, according to Drugs@FDA. RELATED: Are Viagra and Cialis leaving TV advertising? Report forecasts end of ED era on NFL football 2 in FiercePharma’s report in May detailing the top patent losses of 2017. At the time, analysts with life science commercial intelligence firm buy price cialis professional EvaluatePharma predicted the med would lose 96% of its sales by 2022, tumbling to $55 million that year as a host of cheap generics flood the market. There is no indication that the legitimate supply chain is at risk, therefore consumers can be confident that prescription medicines received through legitimate state-licensed pharmacies located in the U.S.
Product Description
Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world’s largest Italian biopharmaceutical company, announced today the completion of its acquisition of Cialis® in the People’s Republic of China from Eli Lilly and Company. Through the acquisition, Menarini will take over ownership of the brand and assume all sales, marketing and distribution responsibilities. Cialis® was first approved by the European Medicines Agency in 2002 followed by the U.S. Food and Drug Administration (“FDA”) in 2003 and then NMPA (National Medical Products Administration) in 2005, as well as in more than 120 other countries.
How long does it take for Cialis to work?
With Cialis®, Menarini intends to strategically expand its nationwide coverage across the Retail, E-Commerce and Hospital channels and deliver on its growth ambition in the second-largest healthcare market worldwide. Besides Men’s Health, Menarini is focused on major therapeutic categories including Dermatology, Allergy/Respiratory, Cardiovascular, Gastroenterology, Pain Management, Consumer Healthcare, Oncology and Anti-Infectives. Maurizio Luongo, Chief Executive Officer, Menarini Asia-Pacific said, “The acquisition of Cialis® is a testament to Menarini’s commitment to invest and grow our well diversified Primary and Speciality Care portfolio in the Asia-Pacific region, which is an increasingly important engine of growth for the Group. We are excited to take the brand from strength to strength in China with our well proven, multi-pronged go-to-market strategy for our Men’s Health portfolio in China. We look forward to harnessing the combined strengths of the complementary products in this portfolio to invigorate lives and relationships across the nation.” Cialis is indicated in China for the treatment of men with erectile dysfunction (ED), and men with both ED and the signs and symptoms of benign prostatic hyperplasia.
Why Should I Pay More For the Same Results?
It is important to note that Cialis is not to be taken with medicines called "nitrates" such as nitroglycerin, as tadalafil may potentiate the hypotensive effect of nitrates; and also GC stimulator, such as riociguat. Menarini Asia-Pacific is a member of the Menarini Group, with a heritage of over 130 years and over 17,000 employees in more than 140 countries. Here in Asia-Pacific, Menarini’s vision is discount cialis online no prescription to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men’s Health. For the Financial Year 2020, the Menarini Group clocked sales revenues of US 4.6 billion dollars, of which the Asia Pacific region has grown to become a dynamic engine of growth for the Group with more than 10% revenue contribution. are safe and effective. Counterfeit versions of Cialis can be identified by the following differences on the label of the bottle when compared to the authentic product.
Medical uses
It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia.” AACHEN, Germany, June 2, 2025 /PRNewswire/ -- Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men[1]. Grünenthal is a global leader in pain management and related diseases. E-Mail: [email protected]Phone: +44 7917 196855 [1] In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men.
Uses and Benefits of Cialis:
Leverage our omni-channel approach to grow your brand across Asia Pacific. The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region. As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.
More FAQ
A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD A. MENARINI ASIA-PACIFIC PRIVATE LIMITED A. MENARINI SINGAPORE PTE LTD A. MENARINI BIOMARKERS SINGAPORE PTE LTD Acquisition of Cialis® in the People’s Republic of China to bolster Menarini’s Men’s Health portfolio and drive multichannel coverage This is a significant milestone for Menarini Asia operations as it commemorates its 10th anniversary of being established in 13 major healthcare markets in Asia-Pacific 22/07/21, Singapore – A.